Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens Academic Article uri icon

Overview

MeSH Major

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Cross Infection
  • Methicillin-Resistant Staphylococcus aureus
  • Pneumonia, Staphylococcal
  • Vancomycin

abstract

  • The primary end point of the studies was met, indicating that telavancin is noninferior to vancomycin on the basis of clinical response in the treatment of HAP due to gram-positive pathogens.

publication date

  • January 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3060890

Digital Object Identifier (DOI)

  • 10.1093/cid/ciq031

PubMed ID

  • 21148517

Additional Document Info

start page

  • 31

end page

  • 40

volume

  • 52

number

  • 1